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Abstract
Background: Nigella sativa (NS), a member of family Ranunculaceae is commonly known as black seed or kalonji. It
has been well studied for its therapeutic role in various diseases, particularly cancer. Literature is full of bioactive
compounds from NS seed. However, fewer studies have been reported on the pharmacological activity of proteins.
The current study was designed to evaluate the anticancer property of NS seed proteins on the MCF-7 cell line.
Methods: NS seed extract was prepared in phosphate-buffered saline (PBS), and proteins were precipitated using
80% ammonium sulfate. The crude seed proteins were partially purified using gel filtration chromatography, and
peaks were resolved by SDS-PAGE. MTT assay was used to screen the crude proteins and peaks for their cytotoxic
effects on MCF-7 cell line. Active Peaks (P1 and P4) were further studied for their role in modulating the expression
of genes associated with apoptosis by real-time reverse transcription PCR. For protein identification, proteins were
digested, separated, and analyzed with LC-MS/MS. Data analysis was performed using online Mascot, ExPASy
ProtParam, and UniProt Knowledgebase (UniProtKB) gene ontology (GO) bioinformatics tools.
Results: Gel filtration chromatography separated seed proteins into seven peaks, and SDS-PAGE profile revealed the
presence of multiple protein bands. Among all test samples, P1 and P4 depicted potent dose-dependent inhibitory
effect on MCF-7 cells exhibiting IC50 values of 14.25 ± 0.84 and 8.05 ± 0.22 μg/ml, respectively. Gene expression
analysis demonstrated apoptosis as a possible cell killing mechanism. A total of 11 and 24 proteins were identified
in P1 and P4, respectively. The majority of the proteins identified are located in the cytosol, associate with
biological metabolic processes, and their molecular functions are binding and catalysis. Hydropathicity values were
mostly in the hydrophilic range.
Conclusion: Our findings suggest NS seed proteins as a potential therapeutic agent for cancer. To our knowledge,
it is the first study to report the anticancer property of NS seed proteins.
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Background
Breast cancer is the leading cause of cancer-related
death in women accounting for 2.1 million new cases
and 627,000 deaths globally in 2018 according to the last
release of GLOBOCAN data [1]. Considering the fact of
increasing burden and downside of current therapies
available for breast cancer, search for new effective drugs
is important. One most prominent hallmark in all
malignant cells is evasion from apoptosis and is triggered
either by the intrinsic mitochondrial pathway or extrin-
sic death receptor-mediated pathway [2]. Irrespective of
the pathway involved in apoptosis, the execution is me-
diated by a cascade of cysteine-aspartic proteases named
as caspases that are further categorized into initiator cas-
pases (caspase 2, 8, 9 and 10) and executioner caspases
(caspase 3, 6 and 7). Therefore, inducing apoptosis is a
pivotal approach in fighting against tumor [3].
Historically, compounds derived from medicinal plants
serve as a promising source of pharmaceuticals for nu-
merous ailments. According to the World Health
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Organization (WHO), more than 80% of the population
around the globe depend entirely on medicinal plants
and herbal remedies for their treatment [4]. Plant-
derived compounds account for more than 60% of the
approved anticancer drugs [5, 6], including taxol, vincris-
tine, vinblastine, and camptothecin derivatives [7]. Despite
years of research and many treatment options available
toxicity, off-targets, drug resistance, and limited bioavail-
ability remain a challenge on the way to complete cure.
With the advancement in proteomics, protein-based drugs
emerged out as a potential anticancer agent [8]. These
drugs offer many advantages over small molecules as they
are highly potent and selective therefore, less toxic [9].
Medicinal plants are a rich source of biologically active
proteins and peptides particularly those belonging to Sola-
naceae, Ranunculaceae, Brassicaceae, Asteraceae, Faba-
ceae, and Cucurbitaceae families [10]. Evaluation of
protein and peptides from these families for their antican-
cer potential could provide a piece of preliminary informa-
tion for the selection of plants with potent antitumor
activity for future studies.
Nigella sativa (NS), a medicinal herb frequently known
as black seed or Kalonji, is a member of a Ranuncula-
ceae family, well known for its pharmacological action
against various human diseases [11]. Its cultivation is na-
tive to Southwest Asia, Southern Europe, and North Af-
rica [12]. The seeds of NS reported to contain fats
(28.5%), proteins (26.7%), carbohydrates (24.9%), crude fi-
bers (8.4%) and ash content (4.8%) [13, 14]. To date, more
than 100 bioactive compounds, including thymoquinone,
alkaloids (nigellidine, nigellicine), phenol (carvacol), and
saponin (alpha-hederin) have been reported from NS [15].
These compounds have been shown to possess a wide
range of activities, including anticancer, antimicrobial,
anti-diabetic, analgesic, immunomodulatory, diuretic, anti-
hypertensive, hepatoprotective, spasmolytic, gastro-
protective, renal protective, a bronchodilator, and
antioxidant properties [16]. However, limited litera-
ture is available on the pharmacological activity of NS
seed proteins. Recently, two novel thionins named
NsW1 and NsW2 reported potent against Staphylococ-
cus aureus, Bacillus subtilus and Candida albicans
[17]. Previously, isolated defensin peptides, Ns-D1,
and Ns-D2 have also shown a strong inhibitory re-
sponse against various strains of phytopathogenic
fungi [18]. To the best of our knowledge, proteins
from NS seeds have not been studied for their antican-
cer potential yet. Hence, the present study was de-
signed to demonstrate the effect of NS seed protein
extract and partially purified proteins on human MCF-
7 breast cancer cell line. Their effect on the expression
of pro- and anti-apoptotic genes is also investigated to
determine tumor cell killing mechanisms. Further-
more, active proteins were identified using high-
resolution mass spectrometer and classified based on




NS seeds were bought from the local grocery store of
Karachi, Pakistan. It was, authenticated based on morph-
ology by Dr. Muneeba Khan, Taxonomist at Center for
Plant Conservation, University of Karachi Herbarium,
and Botanical Garden. Voucher specimen has been de-
posited, but no deposition number available. As per in-
stitutional policy, seeds are not accepted as a voucher
specimen for submission; therefore, deposition number
is issued for whole plants only. Debris and other parti-
cles were removed by handpicking, and seeds were
grounded into a fine powder using a food processor.
Protein extraction
The proteins were extracted using a previously described
method with minor modification [19]. In brief, 200 g of
seed powder was dissolved in phosphate-buffered saline
(PBS) 1X, (1:10 w/v) pH 7.2, for overnight at 4 °C with
continuous stirring. Following this, seed extract was cen-
trifuged for 30 min at 4 °C and 10,000 rpm, the super-
natant was separated, and 80% ammonium sulfate was
added to the supernatant at 4 °C. The next day, the pro-
tein precipitates were obtained by centrifugation at simi-
lar conditions. The pellet was dissolved in PBS, dialyzed
in deionized water, and lyophilized.
Gel filtration chromatography
The crude seed protein extract was fractionated on
ÄKTA start (GE Healthcare) fast protein liquid chroma-
tography (FPLC) system equipped with a 280 nm de-
tector and automated fraction collector. A 300mg of
crude seed protein sample was loaded onto Hiload™ 16/
60 Superdex™ 200 pg gel filtration column (GE Health-
care) pre-equilibrated with PBS. All fractions were col-
lected at a flow rate of 1 ml/min (5 ml in each tube), and
absorbance was recorded at 280 nm.
Protein estimation by Bradford assay
The crude seed proteins and gel filtration peaks were
quantified using commercially available Coomassie Brad-
ford assay kit (Thermo Fisher Scientific, USA) following
the provided protocol. Briefly, 5 μl of standard bovine
serum albumin and protein sample were added to 96-well
plate, and 250 μl of Bradford reagent was added and
mixed gently. All the samples were analyzed in triplicates.
After 10min of incubation, absorbance was measured at
595 nm wavelength using a microplate photometer.
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Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE)
The crude proteins of NS seed and gel filtration chroma-
tography peaks were resolved on 4–20% Tris/glycine
precast Mini- PROTEAN TGX gels (Bio-Rad) using
Mini-PROTEAN Tetra Cell assembly (Bio-Rad). A 15 μl
of 2X Laemmli sample buffer (Bio-Rad) containing 2-
mercaptoethanol was mixed with 15 μl (20 μg) of sample,
heated at 95 °C, and run at a constant volt of 200 V for
45 min. To visualize protein bands, the gels were stained
with Coomassie Blue R-250 [20].
Cell culture
The human breast cancer cell line MCF-7 (ATCC HTB-
22™) used in this study was obtained from Dr. Panjwani
Center for Molecular Medicine and Drug Research
(PCMD) Biobank. Cells were maintained in DMEM
medium supplemented with fetal bovine serum (FBS)
10% (v/v) and penicillin-streptomycin 1% (v/v) in a hu-
midified incubator at 37 °C containing 5% CO2.
MTT assay for cell viability
MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetra-
zolium bromide] assay was utilized to measure the anti-
proliferative potential of NS seed proteins [21]. Briefly,
3 × 104 cells /ml were cultured in 96- wells plates in
200 μl of volume and incubated at 37 °C in 5% CO2 for
24 h. The next day, the medium was removed, and for
screening, cells were treated with different concentra-
tions (25, 50, 100, 200, and 400 μg/ml) of NS seed crude
protein and gel filtration chromatography peaks for 48 h.
As only peak 1 (P1) and peak 4 (P4) exhibited cytotoxic
response against MCF-7 therefore, they are further se-
lected for finding IC50 and treated at a dose of (10, 20,
40, and 60 μg/ml) for P1 and (5, 10, 20, and 40 μg/ml)
for P4.In control cells, only medium was added, and
doxorubicin was used as a standard drug. After 48 h,
MTT dye (0.5 mg/ml) prepared in 200 μl medium was
added to the individual well and incubated at 37 °C in
5% CO2 for 4 H. medium containing dye was removed
after incubation, and purple formazan crystals were solu-
bilized in 100 μl of DMSO. Absorbance was recorded at
550 nm wavelength using a Multiskan FC Microplate
Photometer (Thermo Fisher Scientific, USA). The per-
centage of cell inhibition was calculated using the
formula:
Percent Inhibition ¼ O:D:of untreated cells−O:D:of treated cellsð Þx100
O:D:of untreated cells:
RNA isolation and cDNA synthesis
MCF-7 1 × 106 cells/well were seeded in a 6-well plate
and placed in 37 °C incubator having 5% CO2. After 24
h, MCF-7 cells were treated with P1 (10 and 14 μg/ml)
and P4 (5 and 8 μg/ml). The total RNA was isolated by
using TRIzol reagent (Invitrogen) following the manu-
facturer’s instruction. The isolated RNA was run on
1.2% agarose gel electrophoresis for 45 min at 80 V to
determine the integrity and quantified using NanoDrop
2000 Thermo Scientific spectrophotometer. Samples
with high yield, good integrity, and purity ratio 260/280
of ~ 2 were selected for cDNA synthesis. cDNA was syn-
thesized using the RevertAid First Strand cDNA synthe-
sis kit (Thermo Scientific, USA) in Eppendorf®
Mastercycler® Pro thermal cycler (USA) according to
manufacturer’s instructions.
Real time PCR for gene expression analysis
qPCR was performed in Stratagene Mx3000P (Agilent
Technologies, USA) instrument by using Maxima SYBR
Green/ROX qPCR master mix kit (cat# K0221; Thermo
Scientific) as per manufacturer’s protocol. After amplifi-
cation, melting curve analysis was performed by follow-
ing the method; 95 °C for 1 min, 55 °C and 95 °C for 30 s
each. GAPDH was used as a reference gene for the
normalization of data. Fold change in gene expression
was calculated with the CT values obtained by ΔΔct
method.
In-solution digestion
The lyophilized proteins, 1 mg of P1 and P4, were solu-
bilized separately in 100 μl of urea 6M, and reducing
agent 5 μl DTT (200 mM) was added. The samples were
vortexed and incubated at room temperature for 1 h. An
alkylating agent, 20 μl iodoacetamide (200 mM) was
added, and the mixture was incubated at room
temperature in the dark for 1 h. The reaction was
stopped by adding 20 μl of DTT, and urea concentration
was reduced by diluting it with 775 μl of MilliQ water.
Digestion was carried out overnight (< 16 h) by adding
TPCK treated trypsin in a ratio of 1:30 (Trypsin: Pro-
tein). The next day, digestion was stopped by adding
10 μl of acetic acid [22].
Liquid chromatography and ultra-high-resolution mass
spectrometry
The tryptic peptides were separated on BioZen 2.6 μm
Peptide XB-C18 (pore size 100 Å, dimension 150 × 2.1
mm) column (Phenomenex) and analyzed using Impact
II™ UHR-QqTOF (Ultra-High Resolution Qq-Time-Of-
Flight) mass spectrometer (Bruker). The mobile phases
used were 0.1% formic acid in water (solvent A) and
0.1% formic acid in acetonitrile (solvent B). The flow
rate was adjusted to 0.3 ml/min with following 85 min
gradient: from 0 to 5 min 1% B, 5–60min 50% B, 61–65
min 50% B, 65–70min 95% B, 71–78min 95% B, 79–85
min 1% B.
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MS data analysis
Mascot generic files (mgf) generated from raw MS/MS
files were used to search against the SwissProt-
taxonomy Viridiplantae (39,582 sequences) database by
using an in-house licensed Mascot search engine. Mas-
cot search parameters were set as Carbamidomethylation
of cysteine as a fixed modification, oxidation of methio-
nine as variable modification, peptide mass tolerance
allowed was ±1.2 Da, fragment mass tolerance allowed
was ±0.6 Da and trypsin as an enzyme with a maximum
of one mixed cleavage permitted. The false discovery
rate (FDR) was set as 1%. Proteins identified with more
than two matched peptides and greater than 99% prob-
ability were accepted.
Gene ontology annotation and hydropathy profile
The gene ontology annotation of the identified proteins
was obtained from the UniProt Knowledgebase (Uni-
ProtKB) gene ontology (GO) project (https://www.uni-
prot.org/uniprot/). The proteins were categorized based
on their molecular functions, biological process, and cel-
lular localization. To calculate the grand average of hy-
dropathy (GRAVY) value, the FASTA sequence of the
identified proteins was obtained from the UniProt data-
base, and the GRAVY values were computed using on-
line ExPASy tool ProtParam (https://web.expasy.org/
protparam/).
Statistical analysis
SPSS version 20.0 software was used to analyze the data.
One-way ANOVA (analysis of variance) and Dunnett’s
post-hoc test was used for comparing the treatment
groups with control. Results with P values P < 0.05 were
considered statistically significant whereas ***P < 0.001,
**P < 0.01 and *P < 0.05.
Results
Partial purification of Nigella sativa seed proteins
The crude NS seed proteins were successfully precipi-
tated from the extract prepared in PBS using 80% am-
monium sulfate. This step was employed to get rid of
small molecules, including polysaccharides, nucleic
acids, polyphenols, and pigments from the extract.
Whereas, ammonium sulfate has no harmful effects on
protein function and structure [23]. To evaluate the
cytotoxic potential of the crude seed, precipitated pro-
teins were partially purified on gel filtration chromatog-
raphy column Hiload™ 16/60 Superdex™ 200 pg using
ÄKTA start FPLC system. The proteins were eluted
using an elution buffer PBS at 1 ml/min of flow rate, and
absorbance was measured at 280 nm. The eluted frac-
tions were collected 5 ml volume in each tube. Figure 1a
shows the separation of the crude sample into seven
peaks. All the peaks were collected and resolved on the
gel. The Tris/glycine SDS-PAGE analysis of crude pro-
tein revealed the presence of several protein bands
within a range of ~ 2–150 kDa (Fig. 1b). The SDS-PAGE
profile clearly showed protein bands in a molecular
weight range of ~ 5–150 kDa in peak 1 (P1), ~ 15–100
kDa in both peak 2 (P2) & peak 3 (P3) and ~ 5–15 kDa
in peak 4 (P4) (Fig. 1b). Whereas peaks (P5, P6, and P7)
did not show any protein band.
Fig. 1 (a) Elution profile of gel filtration chromatography of protein extract Nigella sativa seeds. The column HiLoad 16/600 Superdex 200 pg pre-
equilibrated with 1X PBS buffer. The flow rate was 1 ml/min, and absorbance monitored at 280 nm. (b) The electrophoretic profile on 4–20% Tris/
glycine SDS PAGE gel. The samples analyzed crude seed proteins (C), gel filtration chromatography peaks (P1, P2, P3, and P4) and standard
molecular weight ladder (L)
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Cytotoxic effect of Nigella sativa on human cancer cell
line
Prior to cytotoxic analysis, all the samples were
desalted by ultrafiltration (3 kDa MWCO) and quanti-
fied by Bradford assay. All the seven peaks and crude
seed proteins were screened at different doses (25, 50,
100, 200, and 400 μg/ml) for their effect on the viabil-
ity of MCF-7 cells. Among all test samples, P1 and
P4 were found to be the most potent and inhibited
cell proliferation in a dose-dependent manner after
48 h of treatment (Fig. 2a & 2b). At 20 μg/ml, P4
inhibited the growth and proliferation to almost 99%
(***P < 0.001) while P1 showed 56.57% (***P < 0.001)
inhibition in MCF-7 cells. The IC50 values calculated
were 14.25 ± 0.84 and 8.05 ± 0.22 μg/ml for P1 and P4,
respectively. Both P1 and P4 were more potent than
standard drug doxorubicin (IC50 value;16 ± 0.01 μg/ml)
(Fig. 2c). As shown in Fig. 3, treatment with P1 and
P4 led to apoptosis related morphological changes in
the cell, such as cell shrinkage and roundness of the
cell. Phase contrast microscopy images clearly show a
decrease in cell count in the treatment groups as
compared to control. These results suggest that pro-
teins from NS seeds exhibited significant inhibitory
activity against MCF-7 cell line.
Analysis of pro-apoptotic and anti-apoptotic genes
To investigate whether P1 and P4 were responsible for in-
ducing apoptosis in MCF- 7 cells, we examined the ex-
pression levels of pro-apoptotic (BAX and CASPASE-3)
and anti-apoptotic (SURVIVIN and BCL-2) genes (Fig. 4).
The intrinsic pathway is strictly regulated by bax to bcl-2
ratio. An increase in BAX expression triggers mitochon-
dria to release cytochrome c that, in return, activates cas-
pases, while bcl-2 inhibits the release [24]. Here, we
observed a significant 1.4-fold (**P < 0.01) change upregu-
lation in BAX and a 0.8 (**P < 0.01) fold change downregu-
lation in BCL-2 gene expression after treatment with P1 at
dose 10 and 14 μg/ml, respectively (Fig. 4a). Subsequently,
the expression of CASPASE-3 increased significantly to
1.7-fold change (**P < 0.01) at 14 μg/ml in P1. The calcu-
lated BAX / BCL-2 ratio, together with significant upregu-
lation in the key executioner, CASPASE-3 indicates the
presence of intrinsic/extrinsic pathway of apoptosis com-
pared to control cells. In contrast, treatment with P4 did
not show any change in bax to bcl-2 ratio when compared
to untreated control cells. However, CASPASE-3 gene ex-
pression was found to be upregulated significantly by 1.4-
fold change (**P < 0.01) at IC50 dose of 8 μg/ml, which
may be due to activation of apoptosis by extrinsic pathway
alone. SURVIVIN, a member of family inhibitors of
Fig. 2 The dose-dependent cytotoxic effect of (a) P1 (b) P4 and (c) doxorubicin on MCF-7 cell line. The IC50 values calculated were 14.25 ± 0.84
for P1, 8.05 ± 0.22 for P4 and 16 ± 0.01 μg/ml for doxorubicin. Data are expressed as a mean of triplicates for each dose ± S.D. from three
independent experiments. UNT labeled bar represents untreated control cells. The statistically significant values are labeled as *P < 0.05, **P < 0.01
and ***P < 0.001 as compared to the control
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apoptosis (IAPs), was also significantly downregulated by
both P1 and P4.
Identification of proteins in P1 and P2 by LC-MS/MS
To identify the proteins present in P1 and P4, in-
solution digestion was performed, followed by LC-
MS/MS, and a mass list obtained was searched
against the UniProt database using the Mascot search
engine. A list of proteins identified is presented in
Tables 1 & 2. A total of 11 proteins were identified
in P1 while 24 proteins in P4. Identified proteins
from P1 and P4 represented a wide pI range from 5.5
to 11.4 and 4.7 to 9.9, respectively, whereas mass
range from 11.4 to 111 kDa and 4.3 to 93.2 kDa, re-
spectively. In P1, the highest significant score of 101
was observed for fructose-bisphosphate aldolase 8,
while histone H4 had the highest 43.7% coverage.
However, in P4, Protein SLE1 was the widely covered
Fig. 3 Phase contrast microscopy images of MCF-7 cells after treatment with P1 and P4
Fig. 4 The effect of Nigella sativa seed proteins on the expression of pro-apoptotic and anti-apoptotic genes. Bar graphs show fold change in
gene expression levels of BAX, CASPASE-3, SURVIVIN, and BCL-2 after treatment with (a) P1 and (b) P4. The data were normalized with GAPDH and
represented as a mean of triplicates for each dose ± S.D. The statistically significant values are labeled as *P < 0.05, ** < 0.01 and ***p < 0.001 as
compared to the untreated control
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protein with 83.9% coverage, and Dehydrin Rab15
presented the highest significant score of 189.
Hydropathy profile
The grand average of hydropathicity (GRAVY) value
for all the identified proteins from P1 and P4 were
calculated, as shown in Fig. 5. The proteins with
positive scores are hydrophobic, and negative scores
are hydrophilic. In P4, both positive and negative
values were observed, indicating the presence of both
hydrophobic and hydrophilic proteins with hydrophilic
being in the majority. While in P1, GRAVY scores
between − 0.6 and − 0.1 indicate only hydrophilic
proteins.
Table 1 The list of proteins identified by Mascot in peak 1(P1)
Identified Protein Accession No. Score Sequence Coverage % Molecular Mass kDa pI
Fructose-bisphosphate aldolase 8 Q9LF98 101 20.4 38.8 6.0
Glyceraldehyde-3-phosphate dehydrogenase 2 Q7FAH2 86 32.9 36.9 6.3
Glucose and ribitol dehydrogenase homolog Q75KH3 81 21.3 32.4 5.7
Peroxygenase Q9SQ57 81 5.30 27.6 5.5
Enolase 2 Q9LEI9 77 17.3 48.1 5.9
Histone H4 Q71V09 75 43.7 11.4 11.4
Ubiquitin-60S ribosomal protein B9DHA6 61 34.4 14.9 9.9
NADPH-dependent aldehyde reductase 1 Q9FZ42 60 17.0 31.6 6.1
Proteasome subunit alpha type-7 O24030 59 22.0 28.6 8.4
Phosphoenolpyruvate carboxylase Q02909 58 18.5 111.0 5.6
Proteasome subunit beta type 4 Q7DLR9 57 39.0 27.7 6.0
Table 2 The list of proteins identified by Mascot in peak 4 (P4)
Identified Protein Accession No. Score Sequence Coverage % Molecular Mass kDa pI
Dehydrin Rab15 Q00742 189 21.5 15.7 9.9
Carrot ABA-induced in somatic embryos 3 Q5KTS7 180 32.7 12.1 6.1
Protein SLE1 I1N2Z5 150 83.9 12.2 5.3
Em-like protein GEA6 Q02973 85 14.1 9.9 6.7
Ubiquitin-NEDD8-like protein RUB1 Q9SHE7 146 28.8 17.4 5.7
Phosphoglycerate kinase P12783 135 21.7 42.1 5.6
60S ribosomal protein L12 O50003 99 14.5 17.9 9.0
ATP synthase subunit beta Q01859 91 25.2 59.0 5.9
Enolase 1 Q9LEJ0 88 34.6 48.0 5.5
Enolase P42896 82 33.9 48.1 5.5
Bifunctional enolase 2/transcriptional activator P25696 43 33.3 47.9 5.5
Elongation factor 1-alpha P34824 84 12.1 49.4 9.2
Late embryogenesis abundant protein 31 Q9LJ97 78 40.8 26.7 4.7
Em protein P04568 66 41.9 9.9 5.5
Embryonic abundant protein 1 P46520 66 26.3 10.1 5.5
Em protein H2 Q08000 58 44.1 9.9 5.5
Triosephosphate isomerase P12863 72 27.3 27.2 5.5
Thionin NsW1 C0HJH9 69 28.6 4.3 9.6
ADP-ribosylation factor GTPase-activating protein Q5W7F2 60 10.5 93.2 8.3
Late embryogenesis abundant protein 1 O49816 56 34.5 19.0 8.6
Alcohol dehydrogenase class-P P06525 56 32.2 41.8 5.8
ATP synthase subunit alpha P05493 55 23.3 55.2 6.0
Vicilin-like antimicrobial peptides 2–3 Q9SPL3 54 13.9 74.6 6.5
Glyceraldehyde-3-phosphate dehydrogenase P34922 53 23.4 36.7 6.5
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Gene ontology annotation
The identified proteins were further categorized by Uni-
Prot GO annotation based on their cellular localization,
biological process, and molecular functions, as shown in
Fig. 6. Most of the proteins were found to be localized in
cytosol (36%), nucleus (29%) and chloroplast (14%) in P1
(Fig. 6a) while cytosol (56%), nucleus (13%) and mito-
chondrion (13%) in P4 (Fig. 6b). In the category of bio-
logical process 40 and 29% of the identified proteins
were involved in metabolic processes in P1 and P4, re-
spectively. Other major proteins in P1 and P4 were asso-
ciated with response to stress (20%), and cellular process
(17%), respectively. Further molecular functional clas-
sification revealed for P1 was, binding activity (31%),
endopeptidase activity (13%), dehydrogenase activity
(13%), other catalytic activity (13%) and for P4 bind-
ing activity (58%), synthase activity (16%) and hydra-
tase activity (11%).
Discussion
Since ancient times natural products have been used for
the treatment of various ailments and remains to be a
widely used form of complementary and alternative
medicine (CAM) alongside allopathic drugs [25, 26]. Re-
cent technological advancement has brought protein and
peptide-based drugs into the spotlight. Plants have
played a historically proven role in drug development
and continue to offer an inexhaustible supply of novel
drug leads [27]. Although 60% of the approved small
molecule based anticancer drugs are plant-derived yet in
Fig. 5 Distribution of the grand average of hydropathicity (GRAVY) value for all the identified proteins in P1 and P4. Positive and negative values
represent hydrophobic and hydrophilic proteins, respectively
Fig. 6 Gene ontology pie charts of all the identified proteins in (a) peak 1 and (b) peak 4. All proteins were classified based on their molecular
function, cellular compartment, and biological process
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reality, only a handful of plants have been explored for
the presence of antitumor proteins and peptides [5]. NS
is one of the most extensively studied plants. Due to its
wide spectrum of pharmacological activities, NS stands
among the top-ranked herbal medicine [28]. Therefore,
it is worthwhile to evaluate the anticancer potential of
NS seed proteins.
In the present study, we successfully demonstrated the
cytotoxic potential of partially purified NS seed proteins
against MCF-7 cells. The crude seed proteins were suc-
cessfully separated into seven peaks on the gel filtration
chromatography column. The tris/glycine SDS PAGE
analysis of both crude and FPLC fractions revealed the
presence of multiple protein bands. Next, we screened
all the peaks (P1, P2, P3, P4, P5, P6, and P7) and crude
seed proteins for their cytotoxic effect. P1 and P4 found
to be the most active against MCF-7, whereas no inhibi-
tory activity was observed in the case of crude and peaks
(P2, P3, P5, P6, and P7). Further, P1 and P4 were tested
at different concentrations for IC50 calculations. Results
showed dose-dependent inhibition in MCF-7 cells after
48 h of treatment. The IC50 value, a dose at which 50%
inhibition observed were calculated as 14.25 ± 0.84 μg/ml
for P1 and 8.05 ± 0.22 μg/ml for P4. These results were
further supported by phase contrast microscopy images,
which also showed a decrease in cell count with the in-
crease in dose. Our results are in accord with the previ-
ous anticancer studies reported from proteins of
medicinal plants Gynura procumbens (longevity spinach)
[29], Corydalis cava (turkey corn) [30], Theobroma ca-
cao (cocoa) [31] and Morinda pubescens (mulberry) [32].
In the subsequent experiment, we investigated the pos-
sible cell killing mechanism exerted by P1 and P4 on
MCF-7 cells. Apoptosis, programmed cell death, is an
important cellular process that is responsible for elimin-
ating the mutated cancer cells [33]. It can be induced by
extrinsic or intrinsic pathways. The intrinsic mitochon-
drial pathway is under the regulation of pro-apoptotic
(e.g., Bax) and anti-apoptotic (e.g., Bcl-2) genes. The
major player in apoptosis are caspases that are respon-
sible for the execution of apoptosis. Evasion from apop-
tosis is the most prominent hallmark of cancer cells
[34]. Hence, activation of apoptosis is an intriguing ap-
proach to fight against malignancy. Herein, apoptosis
was induced in human breast MCF-7 cancer cells by
modulating the expression of BAX, CASPASE-3, SURVI-
VIN, and BCL-2 genes (Fig. 4). At 14 μg/ml in P1, a sig-
nificant upregulation in BAX and a downregulation in
BCL-2 led to an increase in the expression of CASPASE-
3, an executioner of apoptosis. BAX to BCL-2 ratio is
important in determining the fate of the cell for life or
death. Treatment with P1 led to a dose-dependent in-
creased in BAX to BCL-2 ratio, indicating the presence
of a potential anticancer agent. While in the case of P4,
no change in expression of BAX and BCL-2 genes were
observed; however, the CASPASE-3 gene expression was
increased significantly, indicating the activation of the
intrinsic pathway of apoptosis alone. Survivin, a member
of inhibitors of apoptosis (IAPs), is a multifunctional
protein that promotes angiogenesis, inhibits apoptosis,
and controls cell proliferation [35]. Overexpression of
survivin is associated with almost all types of breast can-
cer, including MCF-7 [36, 37]. We observed a significant
decrease in SURVIVIN gene expression, which suggests
apoptosis as a possible killing mechanism in MCF-7 fol-
lowing treatment with P1 and P4.
The active protein fractions were further analyzed
using LC-MS/MS, and data acquired were searched
against the Mascot database for protein identification. In
P1, 11 proteins were identified, and the majority of them
were located in the cytosol and hydrophilic in nature.
Three proteins out of eleven, namely, proteasome sub-
unit alpha type-7, proteasome subunit beta type-4, and
ubiquitin-60S ribosomal protein, are from plant
ubiquitin-proteasome system. Plant proteasome follows
two routes for degradation of damaged or misfolded
proteins, ubiquitin dependent proteolysis, and ubiquitin
independent proteolysis [38]. The latter is crucial for the
removal of oxidized proteins produced by reactive oxy-
gen species [39, 40]. With its additional RNAase activity,
these proteins offer protecting role against plant viruses
such as the tobacco mosaic virus (TMV) [41, 42]. Never-
theless, the involvement of these proteins in the
degradation of proteins and RNA of cancer cells needs
further validation. Another identified protein, fructose-
bisphosphate aldolase 8, belongs to the plant defense re-
lated proteins. This protein has been previously reported
from Gynura procumbens [29] and Corydalis cava tuber
[30] for their antiproliferative effect on MDA-MB-231 and
HeLa cells, respectively. Other identified proteins in P1
were associated with plant metabolic and cellular processes,
and their role as antitumor has not been studied yet.
In the case of P4, 24 proteins, including one peptide,
were identified. The majority of the identified proteins
were hydrophilic in nature, located in the cytosol, and
involved in the metabolic process. Thionin NsW1, an
antimicrobial peptide (AMP) from NS was also identified
in P4. Thionins from different plants are well studied for
their anticancer activity, such as thionin from Pyrularia
pubera (buffalo nut) was reported as cytotoxic to B16
mouse melanoma and HeLa cervical cancer cell lines
[43]. Thionin, namely viscotoxins from Viscum spp in-
duced apoptosis by upregulating the expression of cas-
pase 3 in human lymphocytes [44]. Furthermore,
thionin, Thi2.1 from Arabidopsis thaliana (mouse-ear
cress) inhibited the growth of MCF-7, HeLa, and A549
cancer cell lines [45]. Another identified plant defense
peptide vicilin in P4, also known as antimicrobial
Khurshid et al. BMC Complementary Medicine and Therapies            (2020) 20:5 Page 9 of 11
peptide (AMP), has been reported active against a var-
iety of microbial species [46]. Recently, Gupta et al., have
demonstrated the cytotoxic activity of mungbean vicilin
protein hydrolysate against MDA-MB-231 and MCF-7
breast cancer cell lines. They have also studied the in-
hibitory effect of vicilin peptides on the angiogenesis
converting enzyme (ACE) [47]. Herein, the antiprolifera-
tive and apoptotic effect by P4 could be attributed by
vicilin and/or thionin. Whereas, the pharmacological sig-
nificance of the other identified proteins in P4 has not
been evaluated.
Our study is the preliminary demonstration of the an-
ticancer effects of NS seed proteins. The active protein
fractions consist of a mixture of plant proteins. In the
future, a study will be designed to evaluate the effect of
individual isolated protein and in combination on cancer
cells. The synergistic effect exhibited by the mixture of
proteins in P1 and P4 is an important finding. In fact,
many effective phytomedicines in markets are a crude
mixture of proteins such as bromelain, which is a crude
mixture of various enzymes, including endopeptidases,
glucosidase, cellulase, peroxidase, escharase, and phos-
phatase, from Ananas comosus (pineapple) fruit and
stem [48]. Bromelain is used to treat pain, burns, inflam-
mation, osteoarthritis, cancer, thrombophlebitis, and
sport related injuries [49–53].
Conclusion
Presented studies successfully demonstrated the antipro-
liferative and apoptosis inducing potential of NS seed
proteins on MCF-7 cells. The synergistic behavior by a
mixture of protein in NS protein fractions is an interest-
ing finding. This is the first study from NS seed in this
context and may open an avenue in the future for plant-
based protein pharmaceuticals. However, further studies
are needed to isolate and purify the individual protein
responsible for the In-vitro anticancer effect and to
evaluate the underlying mechanism.
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